| |
“The period 2007 to 2011 will see the expiration of patent
protection for 52 major drugs in the United States, an average of ten a
year. With 2005 seeing a decline in the number of NCEs approved down to
18 from 23 in 2004, there is clear evidence that the loss of revenue
from patent protected drugs will impact upon the growth of the industry
when so few new drugs are reaching the market.“ |
|
| |
The global cancer market has just seen a period of rapid growth.
Between 2003 and 2005, global sales for cancer treating drugs increased
by 40% and now account for more than eight percent of total global
pharmaceutical sales. Although growth rates for this market will slow
due to generic competition the market is predicted to expand to $85.3
billion by 2010 equivalent to CAGR of 11.1% |
|
| |
Pharmaceutical Market Trends, 2006: Key market forecasts & growth
opportunities presents a detailed trend analysis of the global
pharmaceutical market as at the end of 2005 and forecasts until 2010.
The 170 page report presents a series of market forecasts and growth
opportunities in order to help inform pharmaceutical decision-making,
particularly in the areas of corporate planning, portfolio management
and market forecasting.
|
|
| |
Major Pharmaceutical Markets of the Middle East is a comprehensive
report providing extensive coverage of one of the strongest emerging
markets. Through quality analysis and forecasts, this unique report will
allow you to identify market trends and growth potential opportunities.
The report provides the necessary background information for a firm
to operate in the region. |
|
| |
"it must be acknowledged that few pharmaceutical manufacturers, let
along biotech companies are equipped to meet these new health technology
assessment guidelines"
This essential report will help you:
Prepare a global dossier to ensure successful formulary listing
Understand formulary submission guidelines in Australia, UK and USA
Respond to emerging evidentiary and analytical standards
Structure your organisation to make a convincing case to the
regulators |
|
| |
BioGenerics is an umbrella term used to define the market for
bioequivalent products based on the same biological substance used in
off-patent biologics. The BioGeneric market is set to develop slowly in
the major pharmaceutical markets, as a result of regulatory hurdles and
continued protectionism from patented biopharmaceutical marketers. Once
the market does begin to evolve, the biogeneric companies entering the
market early will derive significant value. |
|
| |
National pharmaceutical pricing and reimbursement is a complex and
ever-changing area. In a rapidly globalising market it is essential that
executives are briefed on the regulatory systems that determine the way
in which your company operates and sells its products.
The Guide to Pharmaceutical Pricing and Reimbursement Systems:
Western Europe is a straightforward guide to the pricing and
reimbursement mechanisms in the major European markets. |
|
| |
Understanding the pharmaceutical market in the healthcare system
National pharmaceutical pricing and reimbursement is a complex and
ever-changing area. In a rapidly evolving market it is essential that
executives are briefed on the regulatory systems that determine the way
in which your company operates and sells its products. |
|
